These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 20513529)

  • 1. The loss of 8p23.3 is a novel marker for predicting progression and recurrence of bladder tumors without muscle invasion.
    Eguchi S; Yamamoto Y; Sakano S; Chochi Y; Nakao M; Kawauchi S; Furuya T; Oga A; Matsuyama H; Sasaki K
    Cancer Genet Cytogenet; 2010 Jul; 200(1):16-22. PubMed ID: 20513529
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Superficial (pT2a) and deep (pT2b) muscle invasion in pathological staging of bladder cancer following radical cystectomy.
    Yu RJ; Stein JP; Cai J; Miranda G; Groshen S; Skinner DG
    J Urol; 2006 Aug; 176(2):493-8; discussion 498-9. PubMed ID: 16813876
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bladder cancer stage and outcome by array-based comparative genomic hybridization.
    Blaveri E; Brewer JL; Roydasgupta R; Fridlyand J; DeVries S; Koppie T; Pejavar S; Mehta K; Carroll P; Simko JP; Waldman FM
    Clin Cancer Res; 2005 Oct; 11(19 Pt 1):7012-22. PubMed ID: 16203795
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chromosome 9 deletions and recurrence of superficial bladder cancer: identification of four regions of prognostic interest.
    Simoneau M; LaRue H; Aboulkassim TO; Meyer F; Moore L; Fradet Y
    Oncogene; 2000 Dec; 19(54):6317-23. PubMed ID: 11175346
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic significance of matrix metalloproteinase-1 and tissue inhibitor of metalloproteinase-1 in voided urine samples from patients with transitional cell carcinoma of the bladder.
    Durkan GC; Nutt JE; Rajjayabun PH; Neal DE; Lunec J; Mellon JK
    Clin Cancer Res; 2001 Nov; 7(11):3450-6. PubMed ID: 11705862
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Survivin expression in patients with non-muscle-invasive urothelial cell carcinoma of the bladder.
    Karam JA; Lotan Y; Ashfaq R; Sagalowsky AI; Shariat SF
    Urology; 2007 Sep; 70(3):482-6. PubMed ID: 17905101
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of loss of heterozygosity at chromosome 9p in non-muscle-invasive bladder cancer.
    Ploussard G; Dubosq F; Soliman H; Verine J; Desgrandchamps F; De Thé H; Mongiat-Artus P
    Urology; 2010 Aug; 76(2):513.e13-8. PubMed ID: 20605198
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Loss of P16 expression and chromosome 9p21 LOH in predicting outcome of patients affected by superficial bladder cancer.
    Bartoletti R; Cai T; Nesi G; Roberta Girardi L; Baroni G; Dal Canto M
    J Surg Res; 2007 Dec; 143(2):422-7. PubMed ID: 17612565
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Partial cystectomy for muscle invasive urothelial carcinoma of the bladder: a contemporary review of the M. D. Anderson Cancer Center experience.
    Kassouf W; Swanson D; Kamat AM; Leibovici D; Siefker-Radtke A; Munsell MF; Grossman HB; Dinney CP
    J Urol; 2006 Jun; 175(6):2058-62. PubMed ID: 16697803
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Centrosome hyperamplification predicts progression and tumor recurrence in bladder cancer.
    Yamamoto Y; Matsuyama H; Furuya T; Oga A; Yoshihiro S; Okuda M; Kawauchi S; Sasaki K; Naito K
    Clin Cancer Res; 2004 Oct; 10(19):6449-55. PubMed ID: 15475431
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genomic instability and DNA ploidy are linked to DNA copy number aberrations of 8p23 and 22q11.23 in gastric cancers.
    Kawauchi S; Furuay T; Uchiyama T; Adachi A; Okada T; Nakao M; Oga A; Uchida K; Sasaki K
    Int J Mol Med; 2010 Sep; 26(3):333-9. PubMed ID: 20664948
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical outcome of tumor recurrence for Ta, T1 non-muscle invasive bladder cancer from the data on registered bladder cancer patients in Japan: 1999-2001 report from the Japanese Urological Association.
    Kikuchi E; Fujimoto H; Mizutani Y; Okajima E; Koga H; Hinotsu S; Shinohara N; Oya M; Miki T;
    Int J Urol; 2009 Mar; 16(3):279-86. PubMed ID: 19207609
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Artificial intelligence and bladder cancer arrays.
    Wild PJ; Catto JW; Abbod MF; Linkens DA; Herr A; Pilarsky C; Wissmann C; Stoehr R; Denzinger S; Knuechel R; Hamdy FC; Hartmann A
    Verh Dtsch Ges Pathol; 2007; 91():308-19. PubMed ID: 18314629
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Motility-related protein 1 (MRP-1/CD9) expression in urothelial bladder carcinoma and its relation to tumor recurrence and progression.
    Mhawech P; Herrmann F; Coassin M; Guillou L; Iselin CE
    Cancer; 2003 Oct; 98(8):1649-57. PubMed ID: 14534881
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progression from superficial to invasive carcinoma of the bladder: genetic evidence of either clonal heterogeneous events.
    Volante M; Tizzani A; Casetta G; Zitella A; Pacchioni D; Bussolati G
    Hum Pathol; 2001 May; 32(5):468-74. PubMed ID: 11381363
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gene expression profiling of progressive papillary noninvasive carcinomas of the urinary bladder.
    Wild PJ; Herr A; Wissmann C; Stoehr R; Rosenthal A; Zaak D; Simon R; Knuechel R; Pilarsky C; Hartmann A
    Clin Cancer Res; 2005 Jun; 11(12):4415-29. PubMed ID: 15958626
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene expression signatures predict outcome in non-muscle-invasive bladder carcinoma: a multicenter validation study.
    Dyrskjøt L; Zieger K; Real FX; Malats N; Carrato A; Hurst C; Kotwal S; Knowles M; Malmström PU; de la Torre M; Wester K; Allory Y; Vordos D; Caillault A; Radvanyi F; Hein AM; Jensen JL; Jensen KM; Marcussen N; Orntoft TF
    Clin Cancer Res; 2007 Jun; 13(12):3545-51. PubMed ID: 17575217
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic mapping and DNA sequence-based analysis of deleted regions on chromosome 16 involved in progression of bladder cancer from occult preneoplastic conditions to invasive disease.
    Yoon DS; Li L; Zhang RD; Kram A; Ro JY; Johnston D; Grossman HB; Scherer S; Czerniak B
    Oncogene; 2001 Aug; 20(36):5005-14. PubMed ID: 11526485
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protein expression and gene copy number analysis of topoisomerase 2alpha, HER2 and P53 in minimally invasive urothelial carcinoma of the urinary bladder--a multitissue array study with prognostic implications.
    Krüger S; Lange I; Kausch I; Feller AC
    Anticancer Res; 2005; 25(1A):263-71. PubMed ID: 15816547
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Numerical aberrations of chromosome 17 and the 9p21 locus are independent predictors of tumor recurrence in non-invasive transitional cell carcinoma of the urinary bladder.
    Krüger S; Mess F; Böhle A; Feller AC
    Int J Oncol; 2003 Jul; 23(1):41-8. PubMed ID: 12792774
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.